Effectiveness of boron neutron capture therapy for recurrent head and neck malignancies

Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head-and-Neck Cancer: Final Analysis of a Phase I/II Trial

“…Results from a few small series (11)(12)(13) and case reports (14,15) suggest that BNCT is effective in the treatment of locally recurrent head-and-neck cancer, and that most tumors respond to BNCT.…”

Clinical potential of boron neutron capture therapy for locally recurrent inoperable previously irradiated head and neck cancer

“…Median survival could not be reported in the other 5 trials because a large proportion of the patients were still alive at the study end-point. A wide range of survival assessment from as low as one to two months to as high as 72 months was reported (Kato et al, 2009). However, analysis of survival data was further complicated by a lack of standardisation in the reporting of outcomes.…”

“…Seven phase I and phase II BNCT trials reporting the use of BNCT with intravenous administration of boron-carrier in patients with previously treated loco-regionally recurrent unresectable HNC were identified. Ariyoshi et al, 2007;Kankaanranta et al, 2012;Kato et al, 2009;Kimura et al, 2009;Suzuki et al, 2014;Wang et al, 2011). The EXTREME phase III randomized controlled trial evaluating clinical outcomes of standard systemic therapy in this same category of patients was included to assess standard therapy (Vermorken and Specenier, 2010).…”

“…A survival time of up to 72 months was reported for one patient after receiving seven BNCT treatments over 6 years (Kato et al, 2009). Reports of progression-free survival ranged from 5.1 to 7.9 months (Kankaanranta et al, 2012;Suzuki et al, 2014).…”

Folate receptor-mediated boron-10 containing carbon nanoparticles as potential delivery vehicles for boron neutron capture therapy of nonfunctional pituitary adenomas

“…In the clinic, BNCT is used to treat patients with high-grade gliomas, melanomas, liver metastasis of colon adenocarcinomas, malignant melanomas, recurrent tumors of head and neck cancer, multiple liver tumors and oral cancer [20][21][22][23][24][25]. To the best of our knowledge, the effect of BNCT on PAs has not been tested yet, probably because PAs are benign tumors and general boron compounds have relatively low biologically weighted concentrations in PA tumor cells.…”